Living Cell Technologies (ASX:LCT) has advanced its Parkinson’s disease research with choroid plexus tissue successfully shipped from New Zealand to Australia as part of the third clinical trial of NTCELL.
Choroid plexus tissue shipped to Sydney as NTCELL research advances
August 24, 2022 Australian Biotech
Latest Video
New Stories
-
There is an ideology behind our funding systems, and it's the greatest barrier to change
March 11, 2026 - - Latest News -
New patient-led tool launched in Canberra to transform pain communication
March 10, 2026 - - Latest News -
Leader appointed to drive landmark Sydney biomedical hub toward global health breakthroughs
March 10, 2026 - -
New digital partnership expands access to clinical guidance for Australian healthcare professionals
March 10, 2026 - - Latest News -
Self injection option offers new flexibility for Australians living with Myasthenia Gravis
March 10, 2026 - - Latest News -
CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production
March 10, 2026 - - Latest News -
Labor’s FoI backdown is a welcome victory for transparency and accountability
March 10, 2026 - - Latest News

